Press "esc" to clear
Go to Advanced Search

Showing results

110 of 475

Article ID: 704916

Human Organoids to Speed Drug Development and Personalized Treatments;

American Society for Cell Biology (ASCB)

Bethesda, MD, December 4, 2018 – Human organoids are being hailed as a major development in biomedicine in a report issued by the American Society for Cell Biology (ASCB) to be released Monday, Dec. 10 at a session at the 2018 ASCB|EMBO Meeting in San Diego, CA.

Released:
10-Dec-2018 12:00 PM EST

Article ID: 705008

PET Scans to Optimize Tuberculosis Meningitis Treatments and Personalize Care, Study Finds

Johns Hopkins Medicine

Although relatively rare in the United States, and accounting for fewer than 5 percent of tuberculosis cases worldwide, TB of the brain—or tuberculosis meningitis (TBM)—is often deadly, always hard to treat, and a particular threat to young children.

Released:
6-Dec-2018 10:00 AM EST
  • Embargo expired:
    4-Dec-2018 1:00 PM EST

Article ID: 703884

How Does the Precision Medicine Initiative Affect Me?

Society for Risk Analysis (SRA)

Precision medicine will extend beyond prediction, diagnosis and treatment of disease to also include broader health initiatives, including prevention, nutrition and wellness. These new procedures raise novel legal, policy and ethical issues.

Released:
13-Nov-2018 10:15 AM EST

Article ID: 704683

2018 Value Assessment Challenge Award Recipients to Outline Research Projects at Personalized Medicine Coalition Policy Meeting & Webinar on Dec. 12 in Washington, D.C.

PhRMA Foundation

The PhRMA Foundation and the Personalized Medicine Coalition (PMC) partnered earlier this year for the 2018 Value Assessment Challenge Awards — designed to encourage innovative approaches in defining and measuring value in health care.

Released:
30-Nov-2018 10:05 AM EST
GettyImages-874377002.jpg
  • Embargo expired:
    12-Nov-2018 3:00 PM EST

Article ID: 703354

Risk Score-Guided Care Reduces Mortality Rate in High-Risk Heart Failure Patients by Nearly 50 Percent

Intermountain Medical Center

New team-based care guided by a personalized risk score for heart failure patients reduced the mortality rate of high-risk heart failure patients by nearly 50 percent, according to new research from the Intermountain Medical Center Heart Institute in Salt Lake City.

Released:
5-Nov-2018 9:15 AM EST

Article ID: 703612

Harvard University Receives Transformational Gift for Harvard Medical School

Harvard Medical School

The $200-million commitment will fund: o Fundamental curiosity-driven research and a therapeutics initiative to catalyze the development of new treatments o Integrated data science and artificial intelligence capabilities and applications o Cross-disciplinary research across the Harvard life sciences ecosystem o LifeLab Longwood, an incubator for early-stage, high-potential biotech start-ups In honor of the gift—the largest in Harvard Medical School history—the School will name a research institute for the donor to recognize the pioneering work of its basic science and social science departments.

Released:
8-Nov-2018 10:00 AM EST

Article ID: 702997

Radiation therapy cuts low risk of recurrence by nearly three-fourths for patients with “good risk” breast cancer

American Society for Radiation Oncology (ASTRO)

A subset of patients with low-risk breast cancer is highly unlikely to see cancer return following breast conservation surgery but can lower that risk even further with radiation therapy, finds a new long-term clinical trial report. These 12-year follow-up data from the only prospective, randomized trial to compare recurrence outcomes after treatment for low-risk ductal carcinoma in situ (DCIS) were presented last week at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

Released:
29-Oct-2018 4:45 PM EDT

Article ID: 702600

Pancreatic Cancer Genetic Marker May Predict Outcomes with Radiation Therapy

Thomas Jefferson University

Research scientists find that a gene involved in the immune system called IDO2 plays a significant role in pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. The discovery may help physicians provide better treatment options for patients.

Released:
22-Oct-2018 3:05 PM EDT

Article ID: 702019

PhRMA Foundation and Personalized Medicine Coalition Announce 2018 Value Assessment Challenge Award Recipients

PhRMA Foundation

The PhRMA Foundation and the Personalized Medicine Coalition (PMC) have announced the recipients of the 2018 Value Assessment Challenge Awards – designed to encourage innovative approaches in defining and measuring value in health care.

Released:
10-Oct-2018 4:35 PM EDT

Showing results

110 of 475

Chat now!